Acepodia Enters Strategic Clinical Collaboration with Pfizer to Accelerate Development of Antibody-Cell Conjugation-Based Cell Therapies in Autoimmune Diseases
Acepodia (6976:TT) has entered a strategic clinical collaboration with Pfizer Ignite to accelerate the development of its Antibody-Cell Conjugation (ACC) platform for autoimmune diseases. This partnership will provide Acepodia with access to Pfizer's resources, expertise, and strategic guidance throughout the drug development process. Acepodia's ACC platform, based on Nobel laureate Dr. Carolyn Bertozzi's work, offers an off-the-shelf, non-genetically engineered alternative to CAR-T cell therapy with improved scalability and reduced side effects.
The collaboration will also support Acepodia's ongoing clinical programs, including ACE1831 for non-Hodgkin's lymphoma and ACE2016 for solid tumors. ACE1831 has shown promising results in early clinical trials. This partnership aims to address significant unmet needs in autoimmune diseases while leveraging the potential of cell therapies without the limitations of current CAR-T treatments.
Acepodia (6976:TT) ha avviato una collaborazione clinica strategica con Pfizer Ignite per accelerare lo sviluppo della sua piattaforma di coniugazione anticorpo-cellula (ACC) per malattie autoimmuni. Questa partnership fornirà ad Acepodia accesso alle risorse di Pfizer, all'esperienza e alla guida strategica durante l'intero processo di sviluppo del farmaco. La piattaforma ACC di Acepodia, basata sul lavoro della premio Nobel Dr. Carolyn Bertozzi, offre un alternativa pronta all'uso, non ingegnerizzata geneticamente, alla terapia con cellule CAR-T con una migliore scalabilità e minori effetti collaterali.
La collaborazione supporterà anche i programmi clinici in corso di Acepodia, inclusi ACE1831 per il linfoma non-Hodgkin e ACE2016 per i tumori solidi. ACE1831 ha mostrato risultati promettenti nei primi studi clinici. Questa partnership mira a soddisfare esigenze significative non ancora soddisfatte nelle malattie autoimmuni, sfruttando al contempo il potenziale delle terapie cellulari senza le limitazioni dei trattamenti attuali con CAR-T.
Acepodia (6976:TT) ha iniciado una colaboración clínica estratégica con Pfizer Ignite para acelerar el desarrollo de su plataforma de conjugación de anticuerpos-células (ACC) para enfermedades autoinmunitarias. Esta asociación proporcionará a Acepodia acceso a los recursos, experiencia y orientación estratégica de Pfizer a lo largo de todo el proceso de desarrollo de medicamentos. La plataforma ACC de Acepodia, basada en el trabajo de la ganadora del Premio Nobel, la Dra. Carolyn Bertozzi, ofrece una alternativa lista para usar, no genéticamente modificada, a la terapia con células CAR-T con una mejor escalabilidad y efectos secundarios reducidos.
La colaboración también apoyará los programas clínicos en curso de Acepodia, que incluyen ACE1831 para linfoma no Hodgkin y ACE2016 para tumores sólidos. ACE1831 ha mostrado resultados prometedores en ensayos clínicos iniciales. Esta asociación tiene como objetivo abordar necesidades insatisfechas significativas en enfermedades autoinmunitarias aprovechando el potencial de las terapias celulares sin las limitaciones de los tratamientos actuales con CAR-T.
Acepodia (6976:TT)는 전략적 임상 협력을 Pfizer Ignite와 체결하여 항체-세포 결합 (ACC) 플랫폼의 개발을 가속화하고 있습니다. 이번 파트너십을 통해 Acepodia는 약물 개발 과정 전반에 걸쳐 Pfizer의 자원, 전문성 및 전략적 안내를 받을 수 있습니다. 노벨 수상자인 Carolyn Bertozzi 박사의 연구를 기반으로 한 Acepodia의 ACC 플랫폼은 유전자 조작을 하지 않은 즉시 사용 가능한 CAR-T 세포 치료 대안을 제공하여 향상된 확장성과 낮은 부작용을 갖고 있습니다.
이번 협력은 비호지킨 림프종을 위한 ACE1831과 고형 종양을 위한 ACE2016을 포함한 Acepodia의 지속적인 임상 프로그램도 지원할 것입니다. ACE1831은 초기 임상 시험에서 유망한 결과를 보여주었습니다. 이 파트너십은 현재 CAR-T 치료의 한계를 극복하면서 자가 면역 질환의 중요한 미충족 수요를 해결하는 것을 목표로 하고 있습니다.
Acepodia (6976:TT) a établi une collaboration clinique stratégique avec Pfizer Ignite pour accélérer le développement de sa plateforme de conjugaison anticorps-cellules (ACC) pour les maladies auto-immunes. Ce partenariat fournira à Acepodia un accès aux ressources, à l'expertise et à l'orientation stratégique de Pfizer tout au long du processus de développement du médicament. La plateforme ACC d'Acepodia, basée sur le travail de la lauréate du Prix Nobel, le Dr. Carolyn Bertozzi, offre une alternative clé en main, non génétiquement modifiée à la thérapie cellulaire CAR-T avec une meilleure évolutivité et des effets secondaires réduits.
La collaboration soutiendra également les programmes cliniques en cours d'Acepodia, y compris ACE1831 pour le lymphome non-hodgkinien et ACE2016 pour les tumeurs solides. ACE1831 a montré des résultats prometteurs lors des premiers essais cliniques. Ce partenariat vise à répondre à des besoins non satisfaits significatifs dans les maladies auto-immunes tout en exploitant le potentiel des thérapies cellulaires sans les limitations des traitements CAR-T actuels.
Acepodia (6976:TT) hat eine strategische klinische Zusammenarbeit mit Pfizer Ignite begonnen, um die Entwicklung ihrer Antikörper-Zell-Konjugations (ACC) Plattform für autoimmune Erkrankungen zu beschleunigen. Diese Partnerschaft wird Acepodia Zugang zu den Ressourcen, der Expertise und der strategischen Anleitung von Pfizer während des gesamten Arzneimittelentwicklungsprozesses verschaffen. Die ACC-Plattform von Acepodia, die auf der Arbeit der Nobelpreisträgerin Dr. Carolyn Bertozzi basiert, bietet eine sofort einsatzbereite, nicht genetisch veränderte Alternative zur CAR-T-Zelltherapie mit verbesserter Skalierbarkeit und reduzierten Nebenwirkungen.
Die Zusammenarbeit wird auch die laufenden klinischen Programme von Acepodia unterstützen, darunter ACE1831 für das non-Hodgkin-Lymphom und ACE2016 für solide Tumoren. ACE1831 hat in frühen klinischen Studien vielversprechende Ergebnisse gezeigt. Diese Partnerschaft zielt darauf ab, signifikante unerfüllte Bedürfnisse bei autoimmunen Erkrankungen anzugehen und das Potenzial von Zelltherapien ohne die Einschränkungen der derzeitigen CAR-T-Behandlungen zu nutzen.
- Strategic collaboration with Pfizer Ignite provides access to valuable resources and expertise
- Expansion of ACC platform application into autoimmune diseases, broadening market potential
- ACE1831 shows robust and durable effect in Phase 1 trial for non-Hodgkin's lymphoma
- ACC platform offers improved scalability and reduced side effects compared to CAR-T therapies
- Acepodia retains all rights related to program progress and future partnership opportunities
- None.
Insights
This collaboration marks a significant milestone for Acepodia, potentially accelerating their expansion into autoimmune diseases. The partnership with Pfizer Ignite provides strategic advantages:
- Access to Pfizer's extensive resources and expertise
- Improved clinical trial design and regulatory strategies
- Potential for faster development and market entry
Acepodia's ACC platform, leveraging Nobel Prize-winning technology, offers a promising alternative to CAR-T therapies with reduced side effects and easier scalability. The early success of ACE1831 in NHL trials further validates this approach. This collaboration could significantly enhance Acepodia's market position and accelerate their path to commercialization, potentially disrupting both oncology and autoimmune disease treatment landscapes.
The extension of Acepodia's ACC platform into autoimmune diseases is a game-changing move. Current autoimmune treatments often involve broad immunosuppression, leading to significant side effects. Acepodia's approach could offer targeted therapy without compromising the entire immune system. The potential for an off-the-shelf, non-genetically engineered alternative to CAR-T is particularly exciting, as it could overcome many limitations of current cell therapies in autoimmune conditions, including manufacturing complexities and safety concerns. If successful, this could revolutionize treatment paradigms for diseases like rheumatoid arthritis, lupus and multiple sclerosis, offering more effective and safer options for millions of patients worldwide.
This collaboration significantly de-risks Acepodia's development pipeline and enhances its financial outlook. Key financial implications include:
- Reduced R&D costs through access to Pfizer's resources
- Increased investor confidence, potentially leading to improved stock performance
- Enhanced market potential by expanding into autoimmune diseases, a
$110 billion market by 2028
Importantly, Acepodia retains all rights to its programs, preserving long-term value. This deal structure allows Acepodia to leverage Pfizer's expertise without diluting future profits. Given the company's promising clinical data and this high-profile collaboration, Acepodia could become an attractive acquisition target, potentially driving significant shareholder value in the medium term.
- Through Pfizer Ignite, Acepodia will gain access to Pfizer's resources, scale and expertise as the company broadens the application of its platform beyond oncology into autoimmune diseases
- Pfizer Ignite will also provide strategic advisory support for Acepodia's ongoing clinical programs, ACE1831 in NHL and ACE2016 in solid tumors
- Acepodia's lead ACC platform therapy has shown clinical benefits in oncology without the limitations of current CAR-T cell therapies
Acepodia's ACC platform, which uses bioorthogonal chemistry and is based on the pioneering work of 2022 Nobel laureate Dr. Carolyn Bertozzi, who applied click chemistry to living systems, creates an off-the-shelf, non-genetically engineered version of CAR-T cell therapy that is more easily scaled and avoids cytokine release storms, neurotoxicity, and other side effects associated with CAR-T cell therapies. Acepodia's lead clinical candidate, ACE1831, is currently being evaluated in a Phase 1 first-in-human clinical trial for patients with non-Hodgkin's lymphoma and has demonstrated a robust and durable effect after a single treatment at the lowest dose.
"The significant unmet needs that exist in autoimmune diseases combined with the early positive results that have been seen with CAR-T therapies have opened the door for potential innovations that could provide the efficacy of CAR-T therapy without the challenges that have made routine use of CAR-T in autoimmune diseases difficult," said Sonny Hsiao, Ph.D., chief executive officer of Acepodia. "We see a significant opportunity to bring the benefits of our ACC platform to autoimmune diseases, and working with Pfizer Ignite will position us well to deliver our immunotherapies to patients in desperate need of new options."
By collaborating with Pfizer Ignite, Acepodia will benefit from Pfizer's resources, deep expertise and R&D capabilities, covering multiple stages such as clinical trial design and regulatory strategies to improve the process of developing innovative drugs.
"Pfizer Ignite is focused on supporting the delivery of innovative therapies that are strategically aligned with Pfizer's priority areas and have the potential to address significant gaps in patient care, " said Kathy Fernando, SVP, Head of Pfizer Ignite. "Drawing on Pfizer's deep expertise in oncology and immunology, we look forward to collaborating with Acepodia to help translate their compelling scientific platform into impactful new medicines for patients with unmet need."
With the agreement, Acepodia will retain all rights related to the progress of the program and future partnership opportunities.
About Acepodia
Acepodia is a clinical-stage biotechnology company developing first-in-class cell therapies with its unique Antibody-Cell Conjugation (ACC) platform technology to address gaps in cancer care. Leveraging its ACC technology, the company links tumor-targeting antibodies to its proprietary immune cells, such as natural killer and gamma delta T cells, to create novel ACE therapies, which have increased binding strength against tumors that express low levels of tumor antigens.
Acepodia is composed of seasoned leaders and scientific experts dedicated to advancing its robust pipeline of ACE therapies with the potential to bring innovative, effective, and affordable cell therapies to a broad population of patients across a variety of solid tumors and hematologic cancers. For more information, visit www.acepodia.com and follow Acepodia on Twitter and LinkedIn.
View original content:SOURCE Acepodia Inc.
FAQ
What is the purpose of Acepodia's collaboration with Pfizer Ignite?
How does Acepodia's ACC platform differ from traditional CAR-T cell therapies?
What are the current clinical programs of Acepodia (6976:TT)?
Will Acepodia (6976:TT) retain rights to its programs under the Pfizer Ignite collaboration?
